Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for RIGL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 30.65M
March 31, 2026 2.725M
December 31, 2025 21.98M
September 30, 2025 24.03M
June 30, 2025 30.54M
March 31, 2025 -0.893M
December 31, 2024 14.50M
September 30, 2024 21.68M
June 30, 2024 0.302M
March 31, 2024 -5.013M
December 31, 2023 -6.24M
September 30, 2023 -1.359M
June 30, 2023 5.93M
March 31, 2023 -4.074M
December 31, 2022 -21.91M
September 30, 2022 -13.30M
June 30, 2022 -12.91M
March 31, 2022 -25.64M
December 31, 2021 -19.09M
September 30, 2021 -10.30M
June 30, 2021 55.22M
March 31, 2021 -19.96M
December 31, 2020 -15.57M
September 30, 2020 -19.48M
June 30, 2020 -14.04M
Date Value
March 31, 2020 -3.093M
December 31, 2019 -9.649M
September 30, 2019 -14.64M
June 30, 2019 -16.65M
March 31, 2019 -0.569M
December 31, 2018 11.64M
September 30, 2018 -20.08M
June 30, 2018 -26.99M
March 31, 2018 -23.39M
December 31, 2017 -19.72M
September 30, 2017 -17.61M
June 30, 2017 -19.47M
March 31, 2017 -20.76M
December 31, 2016 -12.46M
September 30, 2016 -22.57M
June 30, 2016 -18.43M
March 31, 2016 -22.42M
December 31, 2015 -13.80M
September 30, 2015 -9.457M
June 30, 2015 -18.15M
March 31, 2015 17.99M
December 31, 2014 -15.05M
September 30, 2014 -18.33M
June 30, 2014 -19.94M
March 31, 2014 -16.43M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Ironwood Pharmaceuticals, Inc. 58.28M
Cytokinetics, Inc. -159.84M
Perspective Therapeutics, Inc. -20.65M
Capricor Therapeutics, Inc. -31.49M
ACADIA Pharmaceuticals, Inc. 100.78M